Indeed, both small molecules inhibiting the tyrosine kinase activity and therapeutic monoclonal antibodies targeting EGFR have been approved for clinical use in NSCLC (Non Small Cell Lung Cancer) and colorectal cancer, whereas agents targeting HER-2 are approved for HER-2-overexpressing breast and gastric cancer. Here, ERBB2 is linked to non-small cell lung carcinoma.